Lanean...
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era
Classical Hodgkin lymphoma (HL) relapses after or is refractory to upfront multiagent chemotherapy in 20%–30% of patients. Effective salvage therapy for relapsed or refractory HL is limited, and advancements are needed. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated...
Gorde:
| Argitaratua izan da: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4418463/ https://ncbi.nlm.nih.gov/pubmed/25696848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/asheducation-2014.1.151 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|